Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRL972 PK in NAFLD/NASH
NCT00794716Phase 2Completed
- Sponsor
- Norgine
- Start
- Jun 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluorescein lisicol in non-alcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), sponsored by Norgine. Started Jun 2008; status: completed.
02
Drugs
fluorescein lisicol
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT00794716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00794716.